ATE475674T1 - Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2 - Google Patents

Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2

Info

Publication number
ATE475674T1
ATE475674T1 AT05789182T AT05789182T ATE475674T1 AT E475674 T1 ATE475674 T1 AT E475674T1 AT 05789182 T AT05789182 T AT 05789182T AT 05789182 T AT05789182 T AT 05789182T AT E475674 T1 ATE475674 T1 AT E475674T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
angiogenic
specific substances
substances available
immunological
Prior art date
Application number
AT05789182T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumsell
Bouteiller Philippe Le
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE475674T1 publication Critical patent/ATE475674T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
AT05789182T 2004-08-09 2005-08-09 Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2 ATE475674T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292015A EP1626059A1 (de) 2004-08-09 2004-08-09 Angiogenische und immunologische Verwendungen von anti-CD160 spezifischen Stoffen, erhältlich vom monoklonalen Antiköper CL1-R2
PCT/EP2005/009231 WO2006015886A1 (en) 2004-08-09 2005-08-09 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2

Publications (1)

Publication Number Publication Date
ATE475674T1 true ATE475674T1 (de) 2010-08-15

Family

ID=34931332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05789182T ATE475674T1 (de) 2004-08-09 2005-08-09 Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2

Country Status (10)

Country Link
US (4) US20090317401A1 (de)
EP (2) EP1626059A1 (de)
JP (1) JP5162239B2 (de)
AT (1) ATE475674T1 (de)
CA (1) CA2576627C (de)
DE (1) DE602005022589D1 (de)
DK (1) DK1776387T3 (de)
ES (1) ES2349015T3 (de)
PL (1) PL1776387T3 (de)
WO (1) WO2006015886A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2236608T3 (en) 2005-10-04 2017-02-20 Soligenix Inc New peptides for the treatment and prevention of immune-related diseases, including the treatment and prevention of infection by modulating natural immunity
EP1880729A1 (de) * 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung des löslichen CD160 zur Unterdrückung der Immunität
EP2210903A1 (de) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Monoklonale Antikörper gegen CD160 und Anwendungen davon
EP2575881B1 (de) * 2010-05-28 2016-09-14 INSERM - Institut National de la Santé et de la Recherche Médicale Spezifische anti-cd160-antikörper zur behandlung von augenerkrankungen auf grundlage von neoangiogenese
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
CN110121508A (zh) 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
FR3061716B1 (fr) 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113613664B (zh) * 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
WO2022013256A1 (en) 2020-07-15 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd160 as a biomarker in acute myeloid leukemia
EP4225792A1 (de) 2020-10-08 2023-08-16 Affimed GmbH Trispezifische bindemittel
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (de) 2021-04-09 2024-02-14 Ose Immunotherapeutics Gerüst für bifunctioanlmoleküle mit pd-1- oder cd28- und sirp-bindenden domänen
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
WO2023170207A1 (en) 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
EP4565610A1 (de) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunktionelles molekül gegen cd28
EP4587122A1 (de) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispezifische antigenbindende proteine zur stimulierung von nk-zellen und verwendung davon
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430846T2 (de) * 1993-08-27 2003-01-16 Dana-Farber Cancer Institute, Boston Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper
AU5253898A (en) * 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
ES2321687T3 (es) * 1999-11-15 2009-06-10 Innate Pharma Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.
FR2828403B1 (fr) * 2001-08-07 2003-10-17 Abtech Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use

Also Published As

Publication number Publication date
WO2006015886A1 (en) 2006-02-16
CA2576627A1 (en) 2006-02-16
EP1626059A1 (de) 2006-02-15
EP1776387B1 (de) 2010-07-28
DE602005022589D1 (de) 2010-09-09
US20090317401A1 (en) 2009-12-24
JP5162239B2 (ja) 2013-03-13
PL1776387T3 (pl) 2011-01-31
JP2008517873A (ja) 2008-05-29
US8444978B2 (en) 2013-05-21
US20150004170A1 (en) 2015-01-01
US20140120110A1 (en) 2014-05-01
CA2576627C (en) 2014-02-18
ES2349015T3 (es) 2010-12-21
US20120003224A1 (en) 2012-01-05
EP1776387A1 (de) 2007-04-25
DK1776387T3 (da) 2010-11-22

Similar Documents

Publication Publication Date Title
DE602005022589D1 (de) Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
DE602005005485D1 (de) Assayvorrichtung und verfahren mit gesteuertem fluss
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
ATE483472T1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
FR2794865B1 (fr) Methode de detection precoce des flavivirus et ses applications
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
NO20073981L (no) Criptobindende molekyler
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
DE602004030341D1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
MX2021011543A (es) Sistemas de fluidos de punto de cuidado y usos de los mismos.
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
ATE526399T1 (de) Neue biologische einheiten und deren verwendung
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
PE20050339A1 (es) Anticuerpos humanos modificados anti-igf-1r
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
TW200510459A (en) RG1 antibodies and uses thereof
EP2275134A3 (de) Verwendung von ADCC-optimierten Antikörpern zur Behandlung von schwachen Patienten
DE60123036D1 (de) Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper, und deren verwendungen
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
EP1660128A4 (de) Anti-fcrn-antikörper zur behandlung von auto/allo-immunzuständen
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
WO2004113500A3 (en) B7s1: an immune modulator